# Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

> **NCT00053001** · PHASE2 · COMPLETED · sponsor: **Fallon Clinic**

## Conditions studied

- Anemia
- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **BIOLOGICAL:** epoetin alfa
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00053001
- **Lead sponsor:** Fallon Clinic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053001, "Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00053001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*